Hot Features
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.025 | -22.7777777778 | 4.5 | 4.5 | 3.115 | 2499 | 3.79652741 | DE |
| 4 | -1.005 | -22.4330357143 | 4.48 | 5.05 | 3.115 | 1382 | 4.20613274 | DE |
| 12 | -1.765 | -33.6832061069 | 5.24 | 5.3 | 3.115 | 1255 | 4.47297549 | DE |
| 26 | -0.025 | -0.714285714286 | 3.5 | 6.16 | 3.115 | 2311 | 4.77037516 | DE |
| 52 | 0.585 | 20.2422145329 | 2.89 | 6.16 | 2.595 | 2984 | 4.18053294 | DE |
| 156 | 0.21 | 6.43185298622 | 3.265 | 6.16 | 1.452 | 1927 | 3.70453758 | DE |
| 260 | 0.21 | 6.43185298622 | 3.265 | 6.16 | 1.452 | 1927 | 3.70453758 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.